Sector News

Merck KGaA in advanced talks to sell off biosims unit

March 10, 2017
Life sciences

The rumors are true: When it comes to biosimilars, Merck KGaA has had enough.

The German drugmaker is in advanced negotiations to sell its unit of biologic copycats, it said in its 2016 annual report (PDF).

The confirmation follows an October report from Reuters that the company had brought on JPMorgan Chase & Co. to help it scout potential buyers for the business. Sources at the time said it could fetch up to $1 billion.

Merck has been collaborating with Indian generics maker Dr. Reddy’s on biosimilars development since 2012, but the team has yet to bring a product to market. Its pipeline includes a copy of AbbVie’s Humira currently in phase 3 testing.

Many of the company’s rivals are further along: Novartis’ Sandoz and Pfizer already have biosimilars on the scene in the U.S., and Amgen’s Humira copy is awaiting launch following a September FDA approval. And as the market begins to crowd, companies still playing catch-up may have to slash prices to nab a piece of the pie. That wouldn’t be good for the latecomers and their revenue prospects—and it would drag down the sales potential for earlier-to-market meds, too.

Merck KGaA isn’t the only drugmaker trying to bail on biosims. Late last month, Allergan CEO Brent Saunders told Bloomberg his company would likely do the same after it wraps up the four cancer-drug copies it’s currently developing with Amgen.

Meanwhile, biosimilars may not be the only unit Merck bids farewell in the near future. Each of the company’s divisions is under an ongoing review, CEO Stefan Oschmann told reporters Thursday, according to Reuters.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.